Perspektywy immunoterapii chorób alergicznych III. Zastosowanie preparatów bakteryjnych i elementów mikroorganizmów w profilaktyce i leczeniu alergii
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2008
Słowa kluczowe:
immunoterapia, receptory TLR, preparaty bakteryjne, choroby alergiczne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Kontakt z mikroorganizmami zarówno chorobotwórczymi, jak i niepatogennymi jest niezbędny do prawidłowego funkcjonowania układu odpornościowego. Wykładnikiem tego jest odpowiednie zbalansowanie czynności limfocytów pomocniczych Th1 i Th2. Różne drobnoustroje, a także pasożyty wielokomórkowe indukują odpowiedź immunologiczną, w którą preferencyjnie zaangażowane są limfocyty Th1 bądź Th2. Ponieważ w olbrzymiej większości chorób alergicznych związanych z nadprodukcją IgE aktywacja subpopulacji Th2 odgrywa dominującą rolę w etiopatogenezie, podejmowane są próby stosowania bakterii bądź elementów drobnoustrojów lub ich pochodnych działających aktywująco na subpopulację Th1 w celu zapobieżenia określonym schorzeniom alergicznym lub ich leczenia.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Lasek , W. (2008). Perspektywy immunoterapii chorób alergicznych III. Zastosowanie preparatów bakteryjnych i elementów mikroorganizmów w profilaktyce i leczeniu alergii. Alergoprofil, 4(1), 12-18. Pobrano z https://journalsmededu.pl/index.php/alergoprofil/article/view/43
Numer
Dział
Artykuł
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Arkwright P.D., David T.J.: Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J. Allergy Clin. Immunol. 2001, 107: 531-534.
2. Adlerberth I., Strachan D.P., Matricardi P.M. et al.: Gut microbiota and development of atopic eczema in 3 European birth cohorts. J. Allergy Clin. Immunol. 2007, 120: 343-350.
3. Bauer S., Hangel D., Yu P.: Immunobiology of toll-like receptors in allergic diseases. Immunobiology 2007, 212: 521-533.
4. Chałubiński M., Kowalski M.L.: Fragmenty bakteryjnego DNA o właściwościach immunomodulacyjnych (CpG) – związek z chorobami alergicznymi. Alergia Astma Immunologia 2003, 8: 1-7.
5. Choi I.S., Koh Y.I.: Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann. Allergy Asthma Immunol. 2002, 88: 584-591.
6. Chu H.W., Honour J.M., Rawlinson C.A. et al.: Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect. Immun. 2003, 71: 1520-1526.
7. Cohon A., Arruda L.K., Martins M.A. et al.: Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J. Allergy Clin. Immunol. 2007, 120: 210-213.
8. Creticos P.S., Shroeder J.T., Hamilton R.G. et al.: Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 2006, 355: 1445-1455.
9. Drachenberg K.J., Wheeler A.W., Stuebner P et al.: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56: 498-505.
10. Flohr C., Tuyen L.N., Lewis S. et al.: Poor sanitation and helminth infection protect against skin sensitization in Vietnamese children: a cross-sectional study. J. Allergy Clin. Immunol. 2006, 118: 1305-1311.
11. Friedberg J.W., Kim H., McCauley M. et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 2005, 105: 489-495.
12. Hessle C., Hanson L.A., Wold A.E.: Lactobacilli colonizing the human gastro-intestinal tract are potent inducers of IL-12. Clin. Exp. Immunol. 1999, 116: 276-282.
13. Higgins D., Marshall J.D., Traquina P. et al.: Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines 2007, 6: 747-759.
14. Hopkin J.M., Shaldon S., Ferry B., et al.: Mycobacterial immunisation in grass polen asthma and rhinitis. Thorax 1998, 53 (supl. 4): S63.
15. Horner A.A.: Toll-like receptor ligands and atopy: a coin with at least two sides. J. Allergy Clin. Immunol. 2006, 117:1133-1140.
16. Kaisho T., Hoshino K., Iwabe T. et al.: Endotoxin can induce MyD88-deficient cells to support T(h)2 cell differentiation. Int. Immunol. 2002, 14: 695-700.
17. Kalliomaki M., Salminen S., Poussa T. et al.: Probiotics and prevention of atopic disease : 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361: 1869-1871.
18. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L.: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med. 2007, 5: 552-559.
19. Krieg A.M.: Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discovery 2006, 5: 471-484.
20. Loubei Z., Dihua S., Jiening W.: Prophylactic effect of BCG vaccination on the recurrence of children asthma. Chin. J. Paediat. 1991, 39: 165-167.
21. Matricardi PM., Rosmini F., Ferrigno L. et al.: Cross-sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. Brit. Med. J. 1997, 314: 999-1003.
22. Matricardi P.M., Bjorksten B., Bonini S. et al.: Microbial products in allergy prevention and therapy. Allergy 2003, 58: 461-471.
23. Medzhitov R.: Recognition of microorganisms and activation of the immune response. Nature 2007, 449: 819-826.
24. Obihara C.C., Beyers N., Gie R.P.: Inverse association between Mycobacterium tuberculosis infection and atopic rhinitis in children. Allergy 2005, 60: 1121-1125.
25. Prescott S.L., Bjorksten B.: Probiotics for the prevention or treatment of allergic diseases. J. Allergy Clin. Immunol. 2007, 120: 255-262.
26. Racila D.M., Kline J.N.: Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J. Allergy Clin. Immunol. 2005, 116: 1202-1205.
27. Riedler J., Braun-Fahrlander C., Eder W. et al.: Early life exposure to farming environment is essential for protection against the development of asthma and allergy: a cross-sectional survey. Lancet 2001, 358: 1129-1133.
28. Rook G.A.W., Hamelmann E., Brunet L.R.: Mycobacteria and allergies. Immunobiology 2007, 212: 461-473.
29. Salkowski C.A., Detore G.R., Vogel S.N.: Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 1997, 65: 3239-3247.
30. Schiffrin E.J., Rochat F., Link-Amster H. et al.: Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J. Dairy Sci. 1995, 78: 491-497.
31. Shaheen S.O., Aaby P., Hall A.J. et al.: Measles and atopy in Guinea-Bissau. Lancet 1996, 347: 1792-1796.
32. Shirakawa T., Enomoto T., Shimazu S.: The inverse association between tuberculin responses and atopic disorder. Science 1997, 275: 77-79.
33. Shirtcliffe P.M., Easthope S.E., Cheng S. et al.: The effect of delipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am. J. Respir. Crit. Care Med. 2001, 163: 1410-1414.
34. Simons F.E.R., Shikishima Y., van Nest G. et al.: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 2004, 113: 1144-1151.
35. Strachan D.P.: Hay fever, hygiene, and household size. Brit. Med. J. 1989, 299: 1259-1260.
36. Szajewska H., Mrukowicz J.: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized double-blind placebo-controlled trials. J. Pediatr. Gastroenterol. Nutr. 2001, 33: S17-S25.
37. Świtaj T., Jalili A., Jakubowska A.B. et al.: CpG immunostimulatory oligodeoxynucleotide (ODN) 1826 enhances antitumor effect of IL-12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. 2004, 10: 4165-4175.
38. Tighe H., Takabayashi K., Schwartz D. et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 2000, 106: 124-134.
39. Tokunaga T., Yamamoto H., Shimada S. et al.: Antitumor activity of deoxynucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 1984, 72: 955-962.
40. Trinchieri G., Sher A.: Cooperation of Toll-like receptor signals in innate immune defence. Nature Rev. Immunol. 2007, 7: 179-190.
41. van den Biggelaar A.H.J., Rodrigues L.C., van Ree R. et al.: Long-term treatment of intestinal helminthes inreeases miete skin-test reactivity in Gabonese schoolchildren. J. Infect. Dis. 2004, 189: 892-900.
42. Vercelli D.: Mechanisms of the hygiene hypothesis – molecular and otherwise. Curr. Opin. Immunol. 2006, 18: 733-737.
43. West A.P., Koblansky A.A., Ghosh S.: Recognition and signaling by Toll-like receptors. Annu. Rev. Cell. Dev. Biol. 206, 22: 409-437.
44. Wheeler A.W., Marshall J.S., Ulrich J.T.: A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 2001, 126: 135-139.
45. Wickens K., Pearce N., Crane J., Beasley R.: Antibiotic use in early childhood and the development of asthma. Clin. Exp. Allergy 1999, 29: 766-771.
46. Yamamoto S., Kuramoto E., Shimada S. et al.: In vitro augmentation of natura killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 1988, 79: 866-873.
47. Zapała Ł., Lasek W.: Naturalne immunostymulatory egzogenne. Post. Biol. Kom. 2007, 34: 581-594.
48. Online: http://www.clinicaltrials.gov/ct2/show/NCT00537355 (Access: 10 marca 2008).
2. Adlerberth I., Strachan D.P., Matricardi P.M. et al.: Gut microbiota and development of atopic eczema in 3 European birth cohorts. J. Allergy Clin. Immunol. 2007, 120: 343-350.
3. Bauer S., Hangel D., Yu P.: Immunobiology of toll-like receptors in allergic diseases. Immunobiology 2007, 212: 521-533.
4. Chałubiński M., Kowalski M.L.: Fragmenty bakteryjnego DNA o właściwościach immunomodulacyjnych (CpG) – związek z chorobami alergicznymi. Alergia Astma Immunologia 2003, 8: 1-7.
5. Choi I.S., Koh Y.I.: Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann. Allergy Asthma Immunol. 2002, 88: 584-591.
6. Chu H.W., Honour J.M., Rawlinson C.A. et al.: Effects of respiratory Mycoplasma pneumoniae infection on allergen-induced bronchial hyperresponsiveness and lung inflammation in mice. Infect. Immun. 2003, 71: 1520-1526.
7. Cohon A., Arruda L.K., Martins M.A. et al.: Evaluation of BCG administration as an adjuvant to specific immunotherapy in asthmatic children with mite allergy. J. Allergy Clin. Immunol. 2007, 120: 210-213.
8. Creticos P.S., Shroeder J.T., Hamilton R.G. et al.: Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 2006, 355: 1445-1455.
9. Drachenberg K.J., Wheeler A.W., Stuebner P et al.: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001, 56: 498-505.
10. Flohr C., Tuyen L.N., Lewis S. et al.: Poor sanitation and helminth infection protect against skin sensitization in Vietnamese children: a cross-sectional study. J. Allergy Clin. Immunol. 2006, 118: 1305-1311.
11. Friedberg J.W., Kim H., McCauley M. et al.: Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-α/β-inducible gene expression, without significant toxicity. Blood 2005, 105: 489-495.
12. Hessle C., Hanson L.A., Wold A.E.: Lactobacilli colonizing the human gastro-intestinal tract are potent inducers of IL-12. Clin. Exp. Immunol. 1999, 116: 276-282.
13. Higgins D., Marshall J.D., Traquina P. et al.: Immunostimulatory DNA as a vaccine adjuvant. Expert Rev. Vaccines 2007, 6: 747-759.
14. Hopkin J.M., Shaldon S., Ferry B., et al.: Mycobacterial immunisation in grass polen asthma and rhinitis. Thorax 1998, 53 (supl. 4): S63.
15. Horner A.A.: Toll-like receptor ligands and atopy: a coin with at least two sides. J. Allergy Clin. Immunol. 2006, 117:1133-1140.
16. Kaisho T., Hoshino K., Iwabe T. et al.: Endotoxin can induce MyD88-deficient cells to support T(h)2 cell differentiation. Int. Immunol. 2002, 14: 695-700.
17. Kalliomaki M., Salminen S., Poussa T. et al.: Probiotics and prevention of atopic disease : 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003, 361: 1869-1871.
18. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L.: Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med. 2007, 5: 552-559.
19. Krieg A.M.: Therapeutic potential of Toll-like receptor 9 activation. Nature Rev. Drug Discovery 2006, 5: 471-484.
20. Loubei Z., Dihua S., Jiening W.: Prophylactic effect of BCG vaccination on the recurrence of children asthma. Chin. J. Paediat. 1991, 39: 165-167.
21. Matricardi PM., Rosmini F., Ferrigno L. et al.: Cross-sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. Brit. Med. J. 1997, 314: 999-1003.
22. Matricardi P.M., Bjorksten B., Bonini S. et al.: Microbial products in allergy prevention and therapy. Allergy 2003, 58: 461-471.
23. Medzhitov R.: Recognition of microorganisms and activation of the immune response. Nature 2007, 449: 819-826.
24. Obihara C.C., Beyers N., Gie R.P.: Inverse association between Mycobacterium tuberculosis infection and atopic rhinitis in children. Allergy 2005, 60: 1121-1125.
25. Prescott S.L., Bjorksten B.: Probiotics for the prevention or treatment of allergic diseases. J. Allergy Clin. Immunol. 2007, 120: 255-262.
26. Racila D.M., Kline J.N.: Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J. Allergy Clin. Immunol. 2005, 116: 1202-1205.
27. Riedler J., Braun-Fahrlander C., Eder W. et al.: Early life exposure to farming environment is essential for protection against the development of asthma and allergy: a cross-sectional survey. Lancet 2001, 358: 1129-1133.
28. Rook G.A.W., Hamelmann E., Brunet L.R.: Mycobacteria and allergies. Immunobiology 2007, 212: 461-473.
29. Salkowski C.A., Detore G.R., Vogel S.N.: Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect. Immun. 1997, 65: 3239-3247.
30. Schiffrin E.J., Rochat F., Link-Amster H. et al.: Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J. Dairy Sci. 1995, 78: 491-497.
31. Shaheen S.O., Aaby P., Hall A.J. et al.: Measles and atopy in Guinea-Bissau. Lancet 1996, 347: 1792-1796.
32. Shirakawa T., Enomoto T., Shimazu S.: The inverse association between tuberculin responses and atopic disorder. Science 1997, 275: 77-79.
33. Shirtcliffe P.M., Easthope S.E., Cheng S. et al.: The effect of delipidated (DDMV) and heat-killed Mycobacterium vaccae in asthma. Am. J. Respir. Crit. Care Med. 2001, 163: 1410-1414.
34. Simons F.E.R., Shikishima Y., van Nest G. et al.: Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J. Allergy Clin. Immunol. 2004, 113: 1144-1151.
35. Strachan D.P.: Hay fever, hygiene, and household size. Brit. Med. J. 1989, 299: 1259-1260.
36. Szajewska H., Mrukowicz J.: Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized double-blind placebo-controlled trials. J. Pediatr. Gastroenterol. Nutr. 2001, 33: S17-S25.
37. Świtaj T., Jalili A., Jakubowska A.B. et al.: CpG immunostimulatory oligodeoxynucleotide (ODN) 1826 enhances antitumor effect of IL-12 gene-modified tumor vaccine in a melanoma model in mice. Clin. Cancer Res. 2004, 10: 4165-4175.
38. Tighe H., Takabayashi K., Schwartz D. et al.: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol. 2000, 106: 124-134.
39. Tokunaga T., Yamamoto H., Shimada S. et al.: Antitumor activity of deoxynucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J. Natl. Cancer Inst. 1984, 72: 955-962.
40. Trinchieri G., Sher A.: Cooperation of Toll-like receptor signals in innate immune defence. Nature Rev. Immunol. 2007, 7: 179-190.
41. van den Biggelaar A.H.J., Rodrigues L.C., van Ree R. et al.: Long-term treatment of intestinal helminthes inreeases miete skin-test reactivity in Gabonese schoolchildren. J. Infect. Dis. 2004, 189: 892-900.
42. Vercelli D.: Mechanisms of the hygiene hypothesis – molecular and otherwise. Curr. Opin. Immunol. 2006, 18: 733-737.
43. West A.P., Koblansky A.A., Ghosh S.: Recognition and signaling by Toll-like receptors. Annu. Rev. Cell. Dev. Biol. 206, 22: 409-437.
44. Wheeler A.W., Marshall J.S., Ulrich J.T.: A Th1-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int. Arch. Allergy Immunol. 2001, 126: 135-139.
45. Wickens K., Pearce N., Crane J., Beasley R.: Antibiotic use in early childhood and the development of asthma. Clin. Exp. Allergy 1999, 29: 766-771.
46. Yamamoto S., Kuramoto E., Shimada S. et al.: In vitro augmentation of natura killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn. J. Cancer Res. 1988, 79: 866-873.
47. Zapała Ł., Lasek W.: Naturalne immunostymulatory egzogenne. Post. Biol. Kom. 2007, 34: 581-594.
48. Online: http://www.clinicaltrials.gov/ct2/show/NCT00537355 (Access: 10 marca 2008).